JP2023517566A - 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 - Google Patents

再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2023517566A
JP2023517566A JP2022554288A JP2022554288A JP2023517566A JP 2023517566 A JP2023517566 A JP 2023517566A JP 2022554288 A JP2022554288 A JP 2022554288A JP 2022554288 A JP2022554288 A JP 2022554288A JP 2023517566 A JP2023517566 A JP 2023517566A
Authority
JP
Japan
Prior art keywords
tetrafluoro
trifluoromethylbenzylamino
compound
neronemdaz
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517566A5 (https=
JPWO2021181159A5 (https=
Inventor
ジュ グワグ，ビョン
サン アン，チュン
ユ ジン，ジン
イ チョ，サン
ズー，ファンメン
シュー，シンリャン
ザン，ウェイキャン
リュー，フシン
ウォン，スーン－ミ
Original Assignee
ジーエヌティー ファーマ カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーエヌティー ファーマ カンパニー， リミテッド filed Critical ジーエヌティー ファーマ カンパニー， リミテッド
Publication of JP2023517566A publication Critical patent/JP2023517566A/ja
Publication of JP2023517566A5 publication Critical patent/JP2023517566A5/ja
Publication of JPWO2021181159A5 publication Critical patent/JPWO2021181159A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022554288A 2020-03-11 2021-03-10 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 Pending JP2023517566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
US62/988,187 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (3)

Publication Number Publication Date
JP2023517566A true JP2023517566A (ja) 2023-04-26
JP2023517566A5 JP2023517566A5 (https=) 2024-03-19
JPWO2021181159A5 JPWO2021181159A5 (https=) 2024-03-19

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554288A Pending JP2023517566A (ja) 2020-03-11 2021-03-10 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529972A (ja) * 2002-06-19 2005-10-06 ニューロテック カンパニー リミテッド テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物
JP2006515370A (ja) * 2003-01-20 2006-05-25 ニューロテック ファーマシューティカルズ カンパニー リミテッド ニューロトロフィンによって誘導される細胞壊死の抑制方法
JP2008546642A (ja) * 2005-05-25 2008-12-25 チョンワエ ファーマ コーポレーション 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法
KR20090113424A (ko) * 2008-04-28 2009-11-02 주식회사 뉴로테크 재관류 손상의 치료 또는 예방용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529972A (ja) * 2002-06-19 2005-10-06 ニューロテック カンパニー リミテッド テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物
JP2006515370A (ja) * 2003-01-20 2006-05-25 ニューロテック ファーマシューティカルズ カンパニー リミテッド ニューロトロフィンによって誘導される細胞壊死の抑制方法
JP2008546642A (ja) * 2005-05-25 2008-12-25 チョンワエ ファーマ コーポレーション 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法
KR20090113424A (ko) * 2008-04-28 2009-11-02 주식회사 뉴로테크 재관류 손상의 치료 또는 예방용 약학 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG, J.M. ET AL.: "Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study pr", TRIALS, vol. 19, 375, JPN7025000993, 2018, pages 1 - 7, ISSN: 0005702659 *
大木 宏一 他: "診療ガイドライン 脳卒中ガイドライン 2015", 日本内科学会雑誌, vol. 106巻, 5号, JPN6025007720, pages 980 - 985, ISSN: 0005702660 *

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
BR112022018136A2 (pt) 2022-10-25
MX2022011214A (es) 2022-10-07
CO2022014343A2 (es) 2023-02-16
AU2021233206A1 (en) 2022-10-06
CN115515573A (zh) 2022-12-23
IL296288B2 (en) 2024-06-01
MX2025012439A (es) 2025-11-03
CA3174709A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12433861B2 (en) Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
US20240366578A1 (en) Treatment of pain and vasoconstriction
US20230330016A1 (en) Colchicine drug-to-drug interactions
KR20150027800A (ko) 경도 인지 장해의 예방 및/또는 치료제
KR102892626B1 (ko) 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도
RS62465B1 (sr) Imatinib za upotrebu u lečenju moždanog udara
ES2249707T3 (es) Tratameinto de combinacion para infarto de miocardio agudo.
WO2023123468A1 (zh) 心脑血管药物及其应用
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
TWI870751B (zh) 心腦血管藥物及其應用
BR122025026201A2 (pt) Composições que compreendem o composto derivado de tetrafluorobenzila, frascos compreendendo as mesmas, uso terapêutico das mesmas e método para preparar o referido composto
US10632132B2 (en) Methods for treating heart transplant rejection
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
WO2016047662A1 (ja) 脳卒中の治療剤
KR101768809B1 (ko) 덱사메타손 및 글리벤클라마이드를 포함하는 뇌졸중의 예방 또는 치료용 약학적 조성물
KR20250106246A (ko) 테트라플루오로벤질 유도체와 저체온 병용치료로 뇌 손상, 장애, 및/또는 사망을 줄이기 위한 조성물 및 방법
WO2024228933A2 (en) Treatments for disturbed cerebral homeostasis
WO2022089544A1 (zh) Bzp在治疗心脑缺血性疾病中的应用
RU2393861C1 (ru) Композиция для лечения рассеянного склероза (варианты)
KR20220014025A (ko) 나파모스타트 메실레이트와 덱사메타손 또는 그 염을 유효성분으로 포함하는 약학적 조성물
JPH0256327B2 (https=)

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206